These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23049491)

  • 21. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging.
    Mahfouz AE; Hamm B; Taupitz M; Wolf KJ
    Radiology; 1993 Jan; 186(1):133-8. PubMed ID: 8416554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
    Golfieri R; Garzillo G; Ascanio S; Renzulli M
    Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gd-EOB-DTPA MRI for focal nodular hyperplasia-like lesions in pediatric cancer survivors.
    Gu K; Jeon TY; Yoo SY; Kim JH
    Eur Radiol; 2021 Jan; 31(1):283-291. PubMed ID: 32797310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nodule in Liver: Investigations, Differential Diagnosis and Follow-up.
    Rao PN
    J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S57-62. PubMed ID: 25755612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.
    Motosugi U; Bannas P; Sano K; Reeder SB
    J Magn Reson Imaging; 2015 Feb; 41(2):251-65. PubMed ID: 25104398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
    Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
    J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
    Grazioli L; Morana G; Kirchin MA; Schneider G
    Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions.
    Haimerl M; Wächtler M; Platzek I; Müller-Wille R; Niessen C; Hoffstetter P; Schreyer AG; Stroszczynski C; Wiggermann P
    BMC Med Imaging; 2013 Dec; 13():41. PubMed ID: 24289722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.
    Park Y; Kim SH; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ; Kim H; Koo JH; Lim HK
    Korean J Radiol; 2010; 11(4):433-40. PubMed ID: 20592927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion-weighted imaging alone and in combination for the diagnosis of liver metastases.
    Donati OF; Fischer MA; Chuck N; Hunziker R; Weishaupt D; Reiner CS
    Eur J Radiol; 2013 May; 82(5):822-8. PubMed ID: 23287713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of Gd-BOPTA- enhanced MRIs and DWI in the diagnosis of intrahepatic mass-forming cholangiocarcinoma.
    Xu CC; Tang YF; Ruan XZ; Huang QL; Sun L; Li J
    Neoplasma; 2017; 64(6):945-953. PubMed ID: 28895422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.
    Matsuda M; Tsuda T; Yoshioka S; Murata S; Tanaka H; Hirooka M; Hiasa Y; Mochizuki T
    Jpn J Radiol; 2014 Jul; 32(7):405-13. PubMed ID: 24854900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
    Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
    Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial.
    Zech CJ; Grazioli L; Breuer J; Reiser MF; Schoenberg SO
    Invest Radiol; 2008 Jul; 43(7):504-11. PubMed ID: 18580333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.